Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

 SummaryNewsCalendarCompanyFinancials 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases.Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS).Multikine is... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Latest news on CEL-SCI CORPORATION
10/13 CEL SCI : receives new European patent for investigational immunotherapy
10/12 CEL SCI : Announces Update on Ongoing Arbitration against Former Clinical Resear..
10/10 CEL SCI : NEW STORY CEL-SCI Granted European Patent for Multikine's Mechanism of..
10/10 CEL SCI : Granted European Patent for Multikine’s Mechanism of Action in M..
10/06 CEL SCI : Announces Update on Ongoing Arbitration against Former Clinical Resear..
10/06 CEL SCI CORP : Entry into a Material Definitive Agreement (form 8-K)
10/05 CEL SCI : NEW STORY CEL-SCI Announces Update on Ongoing Arbitration Against Form..
10/05 CEL SCI : Announces Update on Ongoing Arbitration against Former Clinical Resear..
09/28 CEL SCI : Announces $1.5 Million NIH SBIR Grant to Support Development of Rheuma..
09/20 CEL SCI : Announces $1.5 Million NIH SBIR Grant to Support Development of Rheuma..
More news
Sector news : Bio Therapeutic Drugs
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Bio Therapeutic Drugs
Managers
NameTitle
Geert R. Kersten CEO, CFO, Director & Chief Accounting Officer
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Alexander G. Esterhazy Independent Director
Peter R. Young Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION21
GILEAD SCIENCES11.65%104 788
REGENERON PHARMACEUTICALS20.67%47 421
VERTEX PHARMACEUTICALS107.56%39 091
ACTELION23.24%29 925
GENMAB22.08%13 010